Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Delayed lymphocyte infusion in children given SCT.

T Klingebiel¹, P Bader,

¹Zentrum für Kinder- und Jugendmedizin, Klinik III, Department for Pediatric Hematology and Oncology, Johann Wolfgang Goethe University, Frankfurt/Main, Germany. thomas.klingebiel@kgu.de

Bone Marrow Transplantation

|July 24, 2008

Summary

This summary is machine-generated.

Related Concept Videos

Immunodeficiency Diseases

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Impact of acute GvHD severity on survival and disease relapse in pediatric patients undergoing allogeneic stem cell transplantation for acute lymphoblastic leukemia: an analysis based on the EBMT-PDWP registry.

Bone marrow transplantation·2026

Same author

Interplay between acute graft-versus-host disease and graft-versus-leukemia effect in pediatric acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: implications for relapse incidence and survival - an EBMT PDWP retrospective study.

Bone marrow transplantation·2025

Same author

Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA).

Annals of oncology : official journal of the European Society for Medical Oncology·2021

Same author

Association study of candidate DNA-repair gene variants and acute graft versus host disease in pediatric patients receiving allogeneic hematopoietic stem-cell transplantation.

The pharmacogenomics journal·2021

Same author

Pregnancy and pregnancy outcomes after hematopoietic stem cell transplantation in childhood: a cross-sectional survey of the EBMT Pediatric Diseases Working Party.

Human reproduction (Oxford, England)·2021

Same author

Correction to: No difference in survival after HLA mismatched versus HLA matched allogeneic stem cell transplantation in Ewing sarcoma patients with advanced disease.

Bone marrow transplantation·2021

Donor lymphocyte infusions (DLI) can prevent transplant rejection and relapse by altering chimerism. Close monitoring of hematopoietic chimerism and post-transplant minimal residual disease (MRD) is crucial for successful DLI therapy.

Area of Science:

Hematology
Immunology
Oncology

Background:

Donor lymphocyte infusions (DLI) are a potent immunotherapy used in hematopoietic stem cell transplantation.
DLI can modify chimerism, offering a strategy to prevent graft rejection and disease relapse.
The efficacy of DLI is contingent on a minimal disease burden at the time of infusion.

Purpose of the Study:

To highlight the critical role of monitoring hematopoietic chimerism and minimal residual disease (MRD) post-transplant.
To emphasize the prerequisite of minimal leukemia burden for successful DLI application.
To discuss strategies for mitigating adverse effects like graft-versus-host disease (GvHD).

Main Methods:

Regular monitoring of hematopoietic chimerism.

Related Experiment Videos

Frequent assessment of post-transplant minimal residual disease (MRD).

Administration of DLI using low and escalating doses.

Main Results:

DLI can effectively alter chimerism, leading to prevention of rejection and relapse.
A minimal burden of leukemia or autologous cells is essential for optimal DLI outcomes.
Graft-versus-host disease (GvHD) can be avoided or minimized by using low and increasing DLI doses.

Conclusions:

Close and frequent monitoring (ideally weekly) of hematopoietic chimerism and MRD is recommended for DLI therapy.
Careful patient selection with minimal disease burden is paramount for successful DLI.
DLI administration requires precise dosing strategies to balance efficacy and toxicity, particularly GvHD.